AI and “Data-Driven” technologies revolutionize the pharmaceutical industry, but beware of poor quality data, especially when they concern key opinion leaders!
Failing data has a high cost!
Data relating to quality KOL (Key Opinion Leaders), that is to say precise, updated and connected, is crucial at each stage of the life cycle of a drug. However, it is common to note the use of erroneous data and this can have important consequences on medical and marketing strategies, relationships with health professionals and, ultimately, patients.
● Compromise strategies: Targeting bad experts is waste precious resources. A study shows that early education with the Kols concerned multiplies by 1.5 the adoption of treatment.
● Mailing opportunities: obsolete data can miss influential health professionals, especially during congresses where time is counted. Access to real -time data is essential to optimize interactions.
● Degraded relationships: unrelevant information can affect confidence and compromise future collaborations. The KOLs await personalized exchanges adapted to their professional expertise and practices.
Data challenge disconnected
Even quality data, if they are partitioned, lose their value. The integration of data from different sources is expensive and complex. In addition, these fragmented data is not exploitable by AI, thus limiting the innovation potential.
The asset of “deep” data
The provision of “deep” KOL data, that is to say validated, structured and large-scale connected, make it possible to optimize operational efficiency and decision-making.
● Operational excellence: a considerable time saving for medical and commercial teams, which can focus on the essentials.
● Impacting Kol Interactions: Eased data access allows more relevant and personalized exchanges, thus strengthening relationships with experts.
● IA Effective: “AI-READY” data accelerate the development of models and multiply the use cases.
Invest in data quality: an imperative
In a context where AI transforms the pharmaceutical industry, the quality and connectivity of KOL data are more strategic than ever. Investing in robust data is optimizing innovation, improving operational efficiency and, in the end, accelerating the provision of innovative treatment for patients.
